))
Transmission-Blocking Antigens Show Low Variation, Making Them a Reliable Vaccine Target Across Countries
Manage episode 440491504 series 3531530
Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
A key challenge in developing a malaria vaccine is choosing which stage to target.
Transcript
A key challenge in developing a malaria vaccine is choosing which stage of the infection to target. You can target the parasite when it enters the body, multiplies in the liver and the blood, or is in the sexual stage, preparing to be picked up by a mosquito. Along with selecting the right vaccine target, it’s also important to consider how these targets naturally vary in the population. To identify the optimal target, researchers examined the genetic and structural variation of ten antigens in over 1,000 samples of malaria parasites from six African countries. Interestingly, antigens involved in human infection showed the most genetic and structural variation across countries. Transmission-blocking antigens—ones that induce antibodies in humans that disrupt the parasite’s development in the mosquito, thus preventing further transmission —were more conserved across regions. This makes transmission-blocking antigens excellent targets as standalone or multi-stage vaccines to prevent onward transmission to other people.
Source
Diversity and selection analyses identify transmission-blocking antigens as the optimal solution.
About The Podcast
The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.
73 에피소드
공유
